Meridian Bioscience, Inc. (VIVO) Tops Q2 EPS by 2c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $33.97 --0%
EPS Growth %: -100.0%
Financial Fact:
COST OF SALES: 17.28M
Today's EPS Names:
UXIN, TOWN, NRIM, More
EPS Growth %: -100.0%
Financial Fact:
COST OF SALES: 17.28M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $47.4 million versus the consensus estimate of $44.82 million.
Meridian Bioscience, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Meridian Bioscience, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) tops Q1 earnings, revenue estimates; FY guidance updated
- American Airlines (AAL) Misses Q1 EPS by 7c, Guidance Beats
- Keurig Dr Pepper Inc. (KDP) Tops Q1 EPS by 3c; confirms guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
